Allogene director granted 95,400 RSUs

Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units.

Rhea-AI Filing Summary

Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units. These RSUs give her the right to receive an equal number of Allogene common shares at future vesting dates, without paying an exercise price.

The award will vest in two equal semi-annual installments over one year from the grant date, as long as she continues to provide service through each vesting date. This filing does not report any open-market purchases or sales, only a compensation-related equity grant.

Insider Trade Summary

Grant/Award: 95,400 shares

Grant/Award 1 txn

Insider SATO VICKI L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	95,400	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 95,400 contracts (Direct)

Footnotes (1)

1. F1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

Key Figures

RSUs granted: 95,400 units Price per RSU: $0.00 Underlying common shares: 95,400 shares +1 more

4 metrics

RSUs granted 95,400 units Restricted Stock Units awarded to director on grant date

Price per RSU $0.00 Reported transaction price per Restricted Stock Unit

Underlying common shares 95,400 shares Common stock underlying the RSU award

Vesting period 1 year Two equal semi-annual installments from grant date

Key Terms

Restricted Stock Unit, RSUs, contingent right, vesting date

4 terms

Restricted Stock Unit financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSUs financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Companys Common Stock."

vesting date financial

"The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Allogene Therapeutics (ALLO) director Vicki Sato report in this Form 4?

She reported receiving 95,400 Restricted Stock Units as an equity award. Each RSU represents a right to receive one share of Allogene common stock, subject to vesting over one year and continued service through the vesting dates.

How many Restricted Stock Units were granted to the Allogene (ALLO) director?

The director received 95,400 Restricted Stock Units in this grant. These RSUs convert into the same number of Allogene common shares as they vest, providing stock-based compensation rather than cash, contingent on continued service with the company.

What is the vesting schedule for the 95,400 RSUs at Allogene (ALLO)?

The 95,400 RSUs will vest in two equal semi-annual installments over one year from the grant date. Vesting is contingent on the director’s continued service through each vesting date, so unvested units could be forfeited if service ends earlier.

Does this Allogene (ALLO) Form 4 show any insider stock sales or purchases?

No, the filing only reports an equity award of Restricted Stock Units. There are no open-market share purchases or sales; the transaction is a compensation-related grant with a reported price per unit of $0.00, reflecting no cash paid by the director.

What does each Allogene (ALLO) Restricted Stock Unit represent for the director?

Each RSU represents a contingent right to receive one share of Allogene common stock. The shares are delivered only as the RSUs vest over time, aligning the director’s compensation with the company’s equity performance and continued board service.

How many Allogene (ALLO) shares does the director hold after this RSU grant?

Following this grant, the Form 4 shows the director holding 95,400 derivative securities in the form of RSUs. These units correspond to an equal number of underlying Allogene common shares that will be delivered if and when the RSUs vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/18/2026		A		95,400		(1)	(1)	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)